Dr. Paul Oberstein, a pancreatic cancer expert and member of the Academic GI Cancer Consortium (AGICC), discusses new data showing positive results from a Phase 3 pancreatic cancer study of an experimental drug by Revolution Medicines.
Continue reading2025 ASCO Annual Meeting Recap
The Oncology Consortia of Criterium held their annual Investigator Meetings at the 2025 ASCO Annual Meeting. These gatherings foster an invaluable collaboration and innovation among leading experts in the field, across a wide range of institutions – driving forward our shared mission to advance cancer research and improve patient outcomes.
Continue reading
